Lexicon Pharmaceuticals AI Stock Analysis
Lexicon Pharmaceuticals (LX31) AI Stock Analysis
Lexicon Pharmaceuticals
(Dusseldorf:LX31)
No summary available
Lexicon Pharmaceuticals (LX31) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 796.97M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -12.3
- Beta (1Y)
- 1.44
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Germany
- Employees
- 81
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Lexicon Pharmaceuticals Business Overview & Revenue Model
Company Description
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug...
Lexicon Pharmaceuticals Earnings Call Summary
The call was predominantly positive, with management highlighting completed SONATA-HCM enrollment, encouraging STENO1 safety data, the planned ZYNQUISTA NDA resubmission, regulatory progress through Viatris, a $10 million LX9851 milestone, promising pilavapadin weight-loss data, and a higher cash balance. The principal negatives were lower year-over-year revenue, a larger net loss, higher SG&A expenses, and delays and administrative complexity surrounding the ZYNQUISTA resubmission. Multiple significant clinical and regulatory catalysts expected in the first quarter of 2027 supported an overall favorable tone.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Lexicon maintained its 2026 operating expense guidance of between $100 million and $110 million, with R&D expected to be between $63 million and $68 million and SG&A expected to be between $37 million and $42 million; the company expects SONATA-HCM top-line results in the first quarter of 2027, expects to complete the ZYNQUISTA NDA resubmission in the first quarter of 2027, expects SOTA-CROSS completion in 2027, and expects additional milestone payments as LX9851 advances.
Lexicon Pharmaceuticals Risk Analysis
Lexicon Pharmaceuticals disclosed 38 risk factors in its most recent earnings report. Lexicon Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksLexicon Pharmaceuticals Peers Comparison
Overall Rating
RIGL69Neutral
RGNX51Neutral
BCYC45Neutral
PRTA42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | $837.18M | 2.64 | 73.94% | ― | 2.18% | 165.65% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $505.18M | -2.38 | -203.98% | ― | -4.59% | 8.03% | |
| 45Neutral | $235.88M | -1.66 | -26.02% | ― | 194.79% | 43.93% | |
| 42Neutral | $419.01M | -17.36 | -8.34% | ― | 347.44% | 91.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:LX31 | Lexicon Pharmaceuticals | 1.01 | -0.24 | -19.18% | |
| RIGL | Rigel Pharmaceuticals | 44.46 | 1.95 | 4.59% | |
| PRTA | Prothena Corporation | 8.16 | -2.09 | -20.39% | |
| RGNX | RegenXBio Inc. | 7.64 | -3.50 | -31.42% | |
| BCYC | Bicycle Therapeutics | 3.37 | -3.09 | -47.83% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
